The ASGCT 2026 Annual Meeting (May 11–15, Boston) is the largest cell and gene therapy gathering in the world. But walk the exhibit hall and the story is not just about novel therapies. It is about the supply chain, manufacturing capacity, and commercial infrastructure required to deliver them.
An analysis of the 232 exhibitors in the ASGCT 2026 exhibitor directory — drawn from the official conference platform — reveals a show dominated by service providers rather than therapeutic developers. That composition carries direct implications for market-access teams, CDMO selection, and capacity planning.
The exhibitor base by the numbers
The 232 exhibitors span 19 countries. The United States accounts for 187 exhibitors (81%), reflecting Boston's role as the domestic hub for CGT development and the concentration of US-based CDMOs and tooling vendors.
| Region | Exhibitors | Share |
|---|---|---|
| United States | 187 | 80.6% |
| Europe (8 countries) | 25 | 10.8% |
| Asia-Pacific (5 countries) | 14 | 6.0% |
| Other international | 5 | 2.2% |
China (8 exhibitors), Canada (6), and the United Kingdom (5) are the largest non-US contingents. Germany, France, Japan, and Spain each contribute 3–4 exhibitors.
The international footprint is notably narrow compared with broader biotech conferences. BIO International 2026, for example, draws exhibitors from over 30 countries with international representation above 40%. ASGCT remains a US-centric show, which reflects the current concentration of CGT manufacturing infrastructure in the United States.
Category clusters: a manufacturing-first ecosystem
Of the 232 exhibitors, 105 listed at least one product or service category in the directory, generating 388 category tags across 81 unique categories. Analyzing those tags reveals where the ecosystem's weight sits:
| Category cluster | Tag count | Representative categories |
|---|---|---|
| Gene Therapy | 56 | Gene Therapy, Gene Therapy (general) |
| Viral Vector Manufacturing | 43 | AAV Manufacturing (14), Lentivirus Manufacturing (10), RNA Vectors (8), Adenovirus (4), General Viral Vectors (7) |
| Cell Therapy | 44 | Cell Therapy, Cell Processing, Cell Product Manufacturing |
| Instruments & Equipment | 25 | Scientific Instrumentation, Laboratory Equipment, Imaging Devices |
| Pre-clinical / CRO | 25 | Pre-Clinical Research, Animal Models, Toxicology |
| Reagents & Consumables | 38 | Nucleotides, Plasmids, Enzymes, Growth Media, Purification Reagents |
| Analytical / Assay | 17 | Analytical, Analytical Testing |
| Manufacturing (general) | 14 | Formulation Development, Manufacturing |
| CAR-T / Oncolytics | 13 | CAR-T, Oncolytics |
| Plasmids / Nucleotides | 16 | Plasmids, Nucleotides |
Source: ASGCT 2026 exhibitor directory; analysis by PharmaDossier, run date 2026-06-09.
The combined manufacturing and services footprint is substantial. When counting exhibitors that mention manufacturing, viral vector production, cell processing, fill-finish, or related services in their descriptions or categories, 86 exhibitors (37%) operate in the manufacturing and supply chain layer. An additional 40 exhibitors (17%) are explicitly CDMO or CRO organizations.
AAV capacity leads, lentiviral follows
Within viral vector manufacturing, AAV dominates. Thirty exhibitors specifically reference AAV or adeno-associated virus capabilities, including major CDMOs such as Catalent, Lonza, Thermo Fisher Scientific, and Andelyn Biosciences, alongside specialized vector producers like Oxford Biomedica (OXB), Forge Biologics, Viralgen, and Virovek.
Lentiviral vector manufacturing is represented by 20 exhibitors, including VIVEbiotech, ElevateBio, Biomay, and Porton Advanced Solutions. The gap — 29 AAV-focused exhibitors versus 20 lentiviral-focused — mirrors the current clinical pipeline split, where AAV-based gene therapies (hemophilia, retinal dystrophy, neuromuscular diseases) outnumber ex vivo lentiviral-modified cell therapies in late-stage development.
RNA vector manufacturing appears in 8 category tags, reflecting the emerging class of RNA-based gene delivery platforms but still well behind AAV and lentiviral capacity.
What the segment mix means for commercial teams
The exhibitor composition signals three practical takeaways for drug developers and market-access teams:
1. CDMO and manufacturing capacity remains a seller's market. With 37% of exhibitors in the manufacturing and services layer and CGT pipelines expanding, the supply side has not commoditized. Lead times for GMP viral vector manufacturing at scale remain long, and the presence of major CDMOs (Catalent, Lonza, Thermo Fisher, AGC Biologics, Fujifilm) alongside a long tail of smaller specialized providers suggests both capacity investment and fragmentation.
2. The tooling and reagent layer is underweight relative to demand. Only 18 exhibitors (8%) are primarily tools, reagents, or equipment suppliers. In mature therapeutic modalities like monoclonal antibodies or small molecules, the vendor-to-developer ratio is much higher. The CGT tooling gap — bioreactors sized for viral vector production, closed-cell processing systems, GMP-grade plasmid reagents — represents both a bottleneck and a commercial opportunity.
3. Market-access and payer presence is minimal. The show is overwhelmingly scientific and operational. The absence of payers, specialty pharmacy networks, and market-access consultancies from the exhibitor list reflects a field still in pre-commercial or early-commercial stages for most programs. As more CGT products reach FDA approval and coverage decisions, expect this to shift — and the show's exhibitor mix will be a leading indicator.
Key named exhibitors by segment
| Segment | Companies (selected) |
|---|---|
| Major CDMO | Catalent, Lonza, Thermo Fisher Scientific, Fujifilm, AGC Biologics, SK Pharmteco |
| CGT-specialized CDMO | Andelyn Biosciences, Forge Biologics, OXB (formerly Oxford Biomedica), ElevateBio |
| Viral vector production | Viralgen, Virovek, Biomay, VIVEbiotech, Vector Biolabs |
| Tools & instrumentation | Revvity, Repligen, MilliporeSigma, Malvern Panalytical, Takara Bio |
| Therapeutic developers | Multiple clinical-stage gene therapy companies |
The international capacity question
With 81% of exhibitors US-based, the ASGCT show underscores a real geographic concentration in CGT manufacturing. European and Asia-Pacific CDMO capacity is growing — BioCina (Australia), Curapath (Spain), Biomay (Austria), and Synplogen (Japan) all exhibited — but the center of gravity remains in the United States.
For companies developing CGT products intended for global launch, the exhibitor mix at ASGCT suggests that US-based manufacturing partnerships remain the default, with regional capacity in Europe and Asia still developing. That has implications for regulatory filing strategy (site-specific GMP compliance), cold-chain logistics, and ex-US market-access timelines.
Sources
- ASGCT 2026 exhibitor directory, official conference platform (asgct2026.smallworldlabs.com); analysis by PharmaDossier, run date 2026-06-09.
- ASGCT Annual Meeting official site: annualmeeting.asgct.org.
- BIO International Convention 2026 exhibitor directory (mapyourshow.com) used for cross-conference comparison.
- FDA, "Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application," Guidance for Industry (2025). https://www.fda.gov/media/192321/download
- FDA, "Frequently Asked Questions — Developing Potential Cellular and Gene Therapy Products," Guidance for Industry (November 2024). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/frequently-asked-questions-developing-potential-cellular-and-gene-therapy-products
